1. Introduction {#sec1}
===============

Laser pointers are low-energy light sources emitting focal nonionizing radiation. They are commonly used in several contexts, such as the lecture halls, but also inappropriately as toys for children. Most laser pointer devices are red (670 nm wavelength) or green diode laser (532 nm wavelength).[@bib1]

Recent studies showed that low-power handheld laser pointers can cause retinal damage.[@bib2], [@bib3], [@bib4] Class 3A lasers (output power does not exceed 5 mW, beam power density may not exceed 2.5 mW/cm^2^) may injure the retina with an exposure of 10 seconds, as showed by experiments in monkeys.[@bib3]

As reported by Turaka et al., the morphology of retinal damage from the laser pointers may vary.[@bib4] Clinical findings include: disruption of the foveal ellipsoid zone (the most common OCT finding), subretinal hemorrhage,[@bib5] retinal edema, scars in the retinal pigment epithelium (RPE),[@bib6] foveal granularity,[@bib7] perifoveal drusenoid like deposits/pigment clumps,[@bib8]^,^[@bib9] or ring-shaped hypopigmented lesions in fovea[@bib10]^,^[@bib11] and rarely choroidal neovascularization (CNV).[@bib2]^,^[@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18]

The treatment of CNV secondary to laser injury is still debated. In literature, few cases of CNV secondary to laser injury have been successfully treated by intravitreal bevacizumab.[@bib1]^,^[@bib18]

Here we report the optical coherence tomography angiography (OCTA) findings and treatment outcome in a case of CNV complicating laser maculopathy treated by intravitreal ranibizumab.

2. Case report {#sec2}
==============

A 14-year-old boy presented with loss of vision in his right eye (RE) accompanied by a central scotoma, which appeared after having stared at the beam of a laser pointer. His symptoms had been persisting for one month.

On examination, best-corrected visual acuity (BCVA) was 20/40 in the right eye and 20/20 in the left eye (LE). On fundus biomicroscopy, the right eye presented a small, yellowish-brown, round lesion within the fovea, accompanied by a superficial punctuate hemorrhage. ([Fig. 1](#fig1){ref-type="fig"}A). No anomalies were found on the LE.Fig. 1**Multimodal imaging of choroidal neovascularization secondary to laser injury at baseline.** (A) Color fundus picture of the right eye showing a yellowish-brown lesion within the fovea, accompanied by a superficial hemorrhage *(enlarged view, arrowhead)*. (B) Infrared and SD-OCT showed the typical disruption of ellipsoid zone, the presence of a hyperreflective subfoveal lesion extending from the retinal pigment epithelium into the subretinal space *(arrow),* accompanied by subretinal fluid, with a shadow effect onto the choroidal layer. (C, E) Optical coherence tomography angiography (OCTA) showed on "En face" slab of both ORCC and choriocapillaris segmentations a high flow network. (D, F) B-scan with flow overlay confirming the presence of flow within the lesion seen on the "En face" slabs. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)Fig. 1

Spectral-domain OCT (*Spectralis SD-OCT, Heidelberg Engineering, Heidelberg, Germany*) showed, in correspondence to the round lesion detected on the fundus biomicroscopy, a disruption of ellipsoid zone and the presence of a hyperreflective subfoveal lesion extending from the RPE into the subretinal space, accompanied by a small amount of subretinal fluid; a shadow effect on the choroid was also noted. ([Fig. 1](#fig1){ref-type="fig"}B).

The patient underwent Swept Source OCTA *(PlexElite 9000, Carl Zeiss Meditec, Inc., Dublin, USA),* that revealed on the "En face" slab of both outer retina to choriocapillaris (ORCC) and choriocapillaris segmentations a high flow network corresponding to the focal hyperreflective lesion detected on the SD-OCT ([Fig. 1](#fig1){ref-type="fig"}C, E), suggesting the presence of a CNV. Moreover, B-scan with flow overlay confirmed the presence of flow within the lesion seen on the "En face" slabs. ([Fig. 1](#fig1){ref-type="fig"}D, F), Fluorescein angiography was performed in order to confirm the presence of a subretinal neovascular lesion, well-delineated with early hyperfluorescence and late leakage ([Fig. 2](#fig2){ref-type="fig"}A--C).Fig. 2**Fluorescein angiography at baseline.** (A) Angiographic sequence showing during the early phases a hyperfluorescence corresponding to the neovascular lesion. (B) The fluorescence within the neovascular lesion increased during the intermediate phases, with leakage in late phases (C).Fig. 2

Based on the multimodal imaging, the patient was diagnosed with laser maculopathy complicated by CNV. One injection of ranibizumab was performed in the RE, after parental informed signed consent.

One month follow-up revealed an increase in BCVA on the RE, from 20/40 at baseline to 15/20. Fundus examination revealed a complete resolution of the superficial hemorrhage with a persistent granular aspect of the fovea ([Fig. 3](#fig3){ref-type="fig"}A).Fig. 3**Multimodal imaging of choroidal neovascularization secondary to laser injury at one-month follow-up.** (A) Color fundus picture showing the complete resolution of the superficial hemorrhage with a persistent granular aspect of the fovea. (B) SD-OCT showed a decrease of subfoveal hyperreflectivity, disappearance of subretinal fluid, with a persistent interruption of ellipsoid zone *(asterisk).* (C, E) On OCTA, ORCC and choriocapillaris "En face" slabs" revealed a non-detectable flow within neovascular lesion. (D, F) No flow was detectable on B-scan with flow overlay. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)Fig. 3

SD-OCT showed the disappearance of subretinal fluid, a decrease of subfoveal hyperreflectivity, with a persistent interruption of ellipsoid zone ([Fig. 3](#fig3){ref-type="fig"}B).

On OCTA, flow was no more detected neither the ORCC or the choriocapillaris "En face" slabs", nor on the corresponding B-scan with flow overlay ([Fig. 3](#fig3){ref-type="fig"}C--F).

3. Discussion {#sec3}
=============

We describe the OCTA findings of a case of laser maculopathy complicated by CNV, treated by one intravitreal injection of ranibizumab. To our knowledge, this is the first case describing choroidal neovascularization secondary to laser maculopathy by means of OCTA.

Despite the fact that the RPE is primarily damaged by laser thermal injury, CNV being one of the corollaries,[@bib16], [@bib17], [@bib18], [@bib19], [@bib20] choriocapillaris rarefaction, as demonstrated by OCTA, may also occur, suggesting that the thermal injury is not limited to RPE.[@bib21]

Anti-VEGF treatment of CNV secondary to laser injury is still debated,[@bib4] with few papers reporting the efficacy of intravitreal bevacizumab in CNV complicating laser maculopathy[@bib1]^,^[@bib18] However, our case showed an increase in BCVA, from 20/40 to 15/20 in the month following the intravitreal injection. Moreover, there was a complete regression of exudative signs on SD-OCT, with a persistent focal interruption of the ellipsoid zone. On OCTA, both "En face" slabs and flow overlay B-scans did not detect any flow within the lesion ([Fig. 3](#fig3){ref-type="fig"}C--F).

However, due to the obvious limitations of a single case report, the successful treatment in this case of CNV complicating laser maculopathy needs further investigation.

4. Conclusions {#sec4}
==============

Accidental laser damage to the retina is a rare instance, with few cases reported worldwide. For this reason, non invasive imaging in laser maculopathy, including OCTA, may be useful detect neovascular complications and assess treatment-response.

Patient consent {#sec5}
===============

Parental consent was obtained for the pubblication of this case.

See the attached file.

Funding {#sec6}
=======

No funding or grant support.

Authorship {#sec7}
==========

All authors attest that they meet the current ICMJE criteria for Authorship.

Declaration of competing interest
=================================

The following authors have no financial disclosures:

FA, MFA, PA, AP, AMB, ES, AM.

None.
